Work

Tumor-associated neutrophils and neutrophil-targeted cancer therapies

Year: 2022

Type: review

Abstract: Neutrophils are the frontline cells in response to microbial infections and are involved in a range of inflammatory disorders in the body. In recent years, neutrophils have gained considerable attention in their involvement of complex roles in tumor development and progression. Tumor-associated neutrophils (TANs) that accumulate in local region could be triggered by external stimuli from tumor microenvironment (TME) and switch between anti- and pro-tumor phenotypes. The anti-tumor neutrophils kill tumor cells through direct cytotoxic effects as well as indirect effects by activating adaptive immune responses. In contrast, the pro-tumor phenotype of neutrophils might be associated with cell proliferation, angiogenesis, and immunosuppression in TME. More recently, neutrophils have been proposed as a potential target in cancer therapy for their ability to diminish the pro-tumor pathways, such as by immune checkpoint blockade. This review discusses the complex roles of neutrophils in TME and highlights the strategies in neutrophil targeting in cancer treatment with a particular focus on the progresses of ongoing clinical trials involving neutrophil-targeted therapies.

Source: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

DOI: 10.1016/j.bbcan.2022.188762

Authors: Haiying Que, Qianmei Fu, Tianxia Lan, Xiaohe Tian, Xiawei Wei

Institutions: Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, State Key Laboratory of Biotherapy

Language: English

Topic: Immune cells in cancer

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,740